Prosensa provides postive subset analysis of drisapersen for Duchenne Muscular Dystrophy

Prosensa provides subset analyses on outcomes from drisapersen its investigational antisense oligonucleotide, for Duchenne Muscular Dystrophy boys seven years or younger and those over seven years old as measured by the six-minute walk test (6MWT). In all studies, a treatment difference was seen in the younger patient population. Notably, the preliminary analysis of the 96 week extension data from those participating in the phase III DMD114044 (DEMAND III) study shows a 49 meter difference between those on continual treatment (n=52) and those who had been on placebo for 48 weeks followed by active drug (n=31). Those previously participating in the DMD114117 study (DEMAND II) showed a 52 meter difference at 96 weeks (n=13, n=17, respectively). Prosena stated that the company was encouraged by these results that suggest that treating earlier in the disease and treating longer shows a delay in the progression of the disease.